tradingkey.logo

Prophase Labs Inc

PRPH
0.293USD
+0.001+0.48%
Horarios del mercado ETCotizaciones retrasadas 15 min
12.18MCap. mercado
PérdidaP/E TTM

Prophase Labs Inc

0.293
+0.001+0.48%

Más Datos de Prophase Labs Inc Compañía

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.

Información de Prophase Labs Inc

Símbolo de cotizaciónPRPH
Nombre de la empresaProphase Labs Inc
Fecha de salida a bolsaJan 16, 1984
Director ejecutivoMr. Ted William Karkus
Número de empleados96
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 16
Dirección711 Stewart Ave, Suite 200
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal11530
Teléfono12153450919
Sitio Webhttps://www.prophaselabs.com/
Símbolo de cotizaciónPRPH
Fecha de salida a bolsaJan 16, 1984
Director ejecutivoMr. Ted William Karkus

Ejecutivos de Prophase Labs Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ted William Karkus
Mr. Ted William Karkus
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.22M
--
Dr. Louis Gleckel, M.D.
Dr. Louis Gleckel, M.D.
Independent Director
Independent Director
103.84K
--
Ms. Carolina Abenante, Esq.
Ms. Carolina Abenante, Esq.
Independent Director
Independent Director
--
--
Mr. Steven M. Plumb, CPA
Mr. Steven M. Plumb, CPA
Fractional Chief Financial Officer
Fractional Chief Financial Officer
--
--
Mr. Warren Hirsch, CPA
Mr. Warren Hirsch, CPA
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ted William Karkus
Mr. Ted William Karkus
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.22M
--
Dr. Louis Gleckel, M.D.
Dr. Louis Gleckel, M.D.
Independent Director
Independent Director
103.84K
--
Ms. Carolina Abenante, Esq.
Ms. Carolina Abenante, Esq.
Independent Director
Independent Director
--
--
Mr. Steven M. Plumb, CPA
Mr. Steven M. Plumb, CPA
Fractional Chief Financial Officer
Fractional Chief Financial Officer
--
--
Mr. Warren Hirsch, CPA
Mr. Warren Hirsch, CPA
Independent Director
Independent Director
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: sáb., 18 de oct
Actualizado: sáb., 18 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Karkus (Ted William)
7.74%
Sykon Capital LLC
1.55%
The Vanguard Group, Inc.
0.98%
Geode Capital Management, L.L.C.
0.62%
Hightower Advisors, LLC
0.55%
Otro
88.55%
Accionistas
Accionistas
Proporción
Karkus (Ted William)
7.74%
Sykon Capital LLC
1.55%
The Vanguard Group, Inc.
0.98%
Geode Capital Management, L.L.C.
0.62%
Hightower Advisors, LLC
0.55%
Otro
88.55%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
7.99%
Investment Advisor
4.53%
Hedge Fund
0.98%
Investment Advisor/Hedge Fund
0.91%
Research Firm
0.34%
Venture Capital
0.25%
Otro
85.00%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
85
2.91M
7.01%
-2.64M
2025Q2
91
7.80M
18.77%
+525.30K
2025Q1
95
8.38M
29.57%
+1.62M
2024Q4
97
6.02M
20.15%
-197.61K
2024Q3
101
5.16M
20.53%
-1.27M
2024Q2
102
5.11M
20.47%
-1.25M
2024Q1
100
5.62M
31.27%
-1.27M
2023Q4
102
5.60M
32.69%
-985.39K
2023Q3
105
5.94M
34.65%
-718.97K
2023Q2
102
6.16M
36.72%
-636.57K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Karkus (Ted William)
3.22M
7.74%
--
--
Apr 29, 2025
Sykon Capital LLC
644.79K
1.55%
+644.79K
--
Jun 30, 2025
The Vanguard Group, Inc.
408.27K
0.98%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
259.06K
0.62%
+31.37K
+13.78%
Jun 30, 2025
Hightower Advisors, LLC
229.45K
0.55%
--
--
Jun 30, 2025
Quinn Opportunity Partners LLC
218.13K
0.53%
-100.00K
-31.43%
Jun 30, 2025
Renaissance Technologies LLC
137.92K
0.33%
-161.89K
-54.00%
Jun 30, 2025
Gleckel (Louis)
103.84K
0.25%
--
--
Apr 29, 2025
XTX Markets LLC
102.51K
0.25%
+102.51K
--
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Dimensional US Core Equity 1 ETF
0%
Avantis US Equity ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI